AdventHealth Orlando, Investigational Drug Services — Orlando, Florida

AdventHealth Orlando, Investigational Drug Services is a clinical research site located in Orlando, Florida, United States 32804.

Crixeo Clinical Trials Trust Score: 13/100 (FAILING). This profile has not yet been claimed by the site owner.

AdventHealth Orlando, Investigational Drug Services has participated in 5 clinical trials with 2 currently active.

Therapeutic areas: HER2-positive Breast Cancer, Melanoma, Advanced Solid Tumors.

Sponsors: Seagen, a wholly owned subsidiary of Pfizer, Pfizer, Gilead Sciences.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Orlando

Browse all research sites in Florida · View every site in Orlando

Sponsor Feasibility Report

Trust Score: 13/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for AdventHealth Orlando, Investigational Drug Services?

AdventHealth Orlando, Investigational Drug Services has a Crixeo Trust Score of 13/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has AdventHealth Orlando, Investigational Drug Services conducted?

AdventHealth Orlando, Investigational Drug Services has 5 clinical trials on record, with 2 currently active. Their work covers HER2-positive Breast Cancer, Melanoma, Advanced Solid Tumors.

Is AdventHealth Orlando, Investigational Drug Services accredited by Crixeo Clinical Trials?

AdventHealth Orlando, Investigational Drug Services has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about AdventHealth Orlando, Investigational Drug Services?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.